<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416181</url>
  </required_header>
  <id_info>
    <org_study_id>101MS326</org_study_id>
    <secondary_id>2010-021978-11</secondary_id>
    <nct_id>NCT01416181</nct_id>
  </id_info>
  <brief_title>A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis</brief_title>
  <acronym>ASCEND in SPMS</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of
      the placebo-controlled period (Part 1), participants will have the option of enrolling in a
      2-year open-label extension (Part 2).

      Part 1: The primary objective of the study is to investigate whether treatment with
      natalizumab slows the accumulation of disability not related to relapses in participants with
      secondary progressive multiple sclerosis (SPMS).

      The secondary objectives of Part 1 of this study are to determine the proportion of
      participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in
      participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12),
      the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab
      on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical
      (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24
      using magnetic resonance imaging (MRI) and the proportion of participants experiencing
      progression of disability as measured by individual physical Expanded Disability Status Scale
      (EDSS) system scores.

      Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of
      natalizumab in participants with SPMS.

      The secondary objectives of Part 2 of the study are to investigate long-term disability
      (based on clinical or participant-reported assessments) in participants with SPMS receiving
      natalizumab treatment for approximately 4 years and to assess change in brain volume and T2
      lesion volume.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The ASCEND Study did not achieve statistical significance on the primary or secondary
    endpoints.
  </why_stopped>
  <start_date type="Actual">September 13, 2011</start_date>
  <completion_date type="Actual">April 13, 2016</completion_date>
  <primary_completion_date type="Actual">July 28, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)</measure>
    <time_frame>Up to 96 weeks (2 years)</time_frame>
    <description>Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):
Confirmed progression in EDSS (EDSS score increased from baseline [BL] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);
Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);
Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>218 weeks</time_frame>
    <description>AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of Participants With a T25FW Response</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96</measure>
    <time_frame>Week 24 and Week 96</time_frame>
    <description>Whole brain volume as measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:
an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or
an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.
A confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants With Disability Worsening at 156 Weeks</measure>
    <time_frame>Week 156</time_frame>
    <description>Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS &gt; 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in T25FW</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in T25FW</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in EDSS</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in EDSS</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)</measure>
    <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
    <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in the 6MWT</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score</measure>
    <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
    <description>The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score</measure>
    <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
    <description>The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>Baseline (Part 1) and every 4 weeks from Week 108 to Week 204</time_frame>
    <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in the SDMT</measure>
    <time_frame>Baseline (Part 1) and every 4 weeks from Week 108 to Week 204</time_frame>
    <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire</measure>
    <time_frame>Part 2 Baseline (Week 108) and Weeks 156 and 204</time_frame>
    <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire</measure>
    <time_frame>Part 2 Baseline (Week 108) and Weeks 156 and 204</time_frame>
    <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume</measure>
    <time_frame>Week 24 (Part 1) and Weeks 156 and 204</time_frame>
    <description>Whole brain volume as measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume</measure>
    <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
    <description>Whole grey matter brain volume as measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Summary of New/Enlarging T2 Lesion Counts</measure>
    <time_frame>Baseline (Part 1) up to Week 204</time_frame>
    <description>New or enlarging T2 lesions as measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions</measure>
    <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
    <description>New or enlarging T2 lesions as measured by MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">889</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>natalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natalizumab</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>natalizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tysabri</other_name>
    <other_name>BG00002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo in part 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria (Part 1):

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information in accordance
             with national and local subject privacy regulations.

          -  SPMS defined as relapsing-remitting disease followed by progression of disability
             independent of or not explained by multiple sclerosis (MS) relapses for at least 2
             years.

          -  EDSS score of 3.0 to 6.5, inclusive.

          -  Multiple Sclerosis Severity Score of 4 or higher.

          -  Documented confirmed evidence of disease progression independent of clinical relapses
             over the 1 year prior to enrollment as defined in the Study Reference Guide.

        Key Exclusion Criteria (Part 1):

          -  Relapsing remitting multiple sclerosis (RRMS) or primary progressive MS as defined by
             the revised McDonald Committee criteria.

          -  Clinical relapse (within 3 months) prior to randomization.

          -  T25FW test of &gt;30 seconds during the screening period.

          -  Any value below the lower limit of normal for blood levels of leukocytes, lymphocytes,
             or neutrophils.

          -  Considered by the Investigator to be immunocompromised based on medical history,
             physical examination, laboratory testing, or any other testing required by local
             guidelines, or due to prior immunosuppressive or immunomodulating treatment.

          -  Subjects for whom MRI is contraindicated (i.e., have pacemakers or other
             contraindicated implanted metal devices, are allergic to gadolinium, or have
             claustrophobia that cannot be medically managed).

          -  History of any clinically significant (as determined by the Investigator) cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic (other than MS), dermatologic, psychiatric, and renal, or other major
             disease that would preclude participation in a clinical study.

          -  History of malignant disease, including solid tumors and hematologic malignancies
             (with the exception of basal cell and squamous cell carcinomas of the skin that have
             been completely excised and are considered cured).

          -  Known history of or positive test result for human immunodeficiency virus.

          -  Positive test result for hepatitis C virus (test for hepatitis C virus antibody or
             hepatitis B virus (test for hepatitis B surface antigen and/or hepatitis B core
             antibody).

          -  History of transplantation or any anti-rejection therapy.

          -  Presence of any infectious disease (e.g., cellulitis, abscess, pneumonia, septicemia)
             within 30 days prior to screening.

          -  History of progressive multifocal leukoencephalopathy or other opportunistic
             infections.

        Treatment History (Part 1)

          -  Any prior treatment with cell-depleting therapies, including total lymphoid
             irradiation, cladribine, rituximab, alemtuzumab, or bone marrow ablation.

          -  Any prior treatment with natalizumab.

          -  Treatment with mitoxantrone, cyclophosphamide, cyclosporine, azathioprine,
             methotrexate, mycophenolate mofetil, T cell or T cell receptor vaccination,
             fingolimod, daclizumab, or cytapheresis within 6 months prior to randomization.

          -  Treatment with intravenous or oral corticosteroids, intravenous immunoglobulin, or
             plasmapheresis for treatment of MS within the 3 months prior to randomization.

          -  Treatment with glatiramer acetate or any interferon beta preparations within 4 weeks
             prior to randomization.

          -  Treatment with 4-aminopyridine within 30 days prior to randomization, unless a stable
             dose has been maintained for at least 30 days prior to randomization and will be
             continued for the course of this study.

        Key Inclusion Criteria (Part 2):

          -  Subjects must have participated in and completed Part 1 per protocol, and have
             documented assessment attempts for EDSS, T25FW, and 9HPT prior to first open-label
             dosing.

        Key Exclusion Criteria (Part 2):

          -  Subjects with any significant change in clinical status, including laboratory tests
             that, in the opinion of the Investigator, would make them unsuitable to participate in
             this extension study. The Investigator must re-review the subject's medical fitness
             for participation and consider any diseases that would preclude treatment.

          -  Subjects who discontinued study treatment in Part 1 OR had fewer than 20 infusions in
             Part 1 OR missed 2 or more consecutive infusions in Part 1.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Advance</city>
        <state>North Carolina</state>
        <zip>27006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uniontown</city>
        <state>Ohio</state>
        <zip>44685</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melsbroek</city>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overpelt</city>
        <zip>3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <state>Bohemia</state>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>12111</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arthus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <state>Bouches-du-Rhône</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe et Moselle</state>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salouel</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Wilbad</city>
        <state>Baden Wuerttemberg</state>
        <zip>75323</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hennigsdorf</city>
        <state>Brandenburg</state>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teupitz</city>
        <state>Brandenburg</state>
        <zip>15755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>D4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>D9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baggiovara</city>
        <state>Modena</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cefalu</city>
        <state>Palermo</state>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gallarate</city>
        <state>Varese</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rome</city>
        <zip>00176</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4800 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6130 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plewiska</city>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa-Miedzylesie</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyumen</city>
        <zip>625000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irvine</city>
        <state>Ayrshire</state>
        <zip>KA12 8SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hammersmith</city>
        <state>London</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian Region</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morriston</city>
        <state>Swansea</state>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle</city>
        <state>Tyne</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.tysabri.com</url>
    <description>Find out what to expect with TYSABRI MS treatment</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <results_first_submitted>April 13, 2017</results_first_submitted>
  <results_first_submitted_qc>May 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2017</results_first_posted>
  <disposition_first_submitted>July 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 19, 2016</disposition_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Natalizumab</keyword>
  <keyword>secondary</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>SPMS</keyword>
  <keyword>Tysabri</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Part 1: participants were randomized to receive placebo intravenously (IV) every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Natalizumab 300 mg</title>
          <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="449"/>
                <participants group_id="P2" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew Prior to Dosing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="312">Completed Study through Week 108</participants>
                <participants group_id="P2" count="326">Completed Study through Week 108</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing in Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment for 48 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="98">completed study treatment for 48 weeks in Part 2</participants>
                <participants group_id="P2" count="111">completed study treatment for 48 weeks in Part 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment for 96 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="1">completed study treatment for 96 weeks in Part 2</participants>
                <participants group_id="P2" count="0">completed study treatment for 96 weeks in Part 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment for &gt; 96 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="267"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population: all participants who were randomized and received at least 1 infusion of study treatment in Part 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Natalizumab 300 mg</title>
          <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="449"/>
            <count group_id="B2" value="439"/>
            <count group_id="B3" value="888"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20 - 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 - 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 - 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)</title>
        <description>Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):
Confirmed progression in EDSS (EDSS score increased from baseline [BL] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);
Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);
Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.</description>
        <time_frame>Up to 96 weeks (2 years)</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)</title>
          <description>Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):
Confirmed progression in EDSS (EDSS score increased from baseline [BL] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);
Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);
Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed on ≥1 of EDSS, T25FW, or 9HPT at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="43.1" upper_limit="52.4"/>
                    <measurement group_id="O2" value="44" lower_limit="39.8" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on EDSS at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="11.7" upper_limit="18.3"/>
                    <measurement group_id="O2" value="16" lower_limit="12.3" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on T25FW at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="30.8" upper_limit="39.7"/>
                    <measurement group_id="O2" value="35" lower_limit="30.4" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on 9HPT (either hand) at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="19.3" upper_limit="27.1"/>
                    <measurement group_id="O2" value="15" lower_limit="11.3" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on 9HPT (dominant hand) at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10.2" upper_limit="16.5"/>
                    <measurement group_id="O2" value="10" lower_limit="7.2" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on 9HPT (non-dominant hand) at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12.5" upper_limit="19.2"/>
                    <measurement group_id="O2" value="10" lower_limit="7.2" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on ≥ 1 of EDSS, T25FW, or 9HPT at 2 years</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2866</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on EDSS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7530</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on T25FW</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9137</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on 9HPT (either hand)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on 9HPT (dominant hand)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1251</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on 9HPT (non-dominant hand)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0091</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.</description>
        <time_frame>218 weeks</time_frame>
        <population>Safety population: all participants who were randomized in Part 1 and received at least 1 infusion of study treatment in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.</description>
          <population>Safety population: all participants who were randomized in Part 1 and received at least 1 infusion of study treatment in Part 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or severe event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation of treatment due to event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal from study due to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Percentage of Participants With a T25FW Response</title>
        <description>T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of Participants With a T25FW Response</title>
          <description>T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="12.7" upper_limit="20.3"/>
                    <measurement group_id="O2" value="19" lower_limit="14.6" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4369</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for baseline EDSS (&lt;=5.5 or &gt;=6) and T25FW.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)</title>
        <description>MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.</description>
        <time_frame>Baseline and Week 96</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)</title>
          <description>MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="21.061"/>
                    <measurement group_id="O2" value="2.70" spread="22.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5409</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between the active and placebo groups at Week 96 is based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or &gt;=6) and BL MSWS-12.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire</title>
        <description>The ABILHAND Questionnaire measures the participant’s perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND.</description>
        <time_frame>Baseline and Week 96</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire</title>
          <description>The ABILHAND Questionnaire measures the participant’s perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.45" spread="14.739"/>
                    <measurement group_id="O2" value="-2.44" spread="13.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2586</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo groups at Week 96 is based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or &gt;=6) and BL ABILHAND.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score</title>
        <description>The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant’s perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
        <time_frame>Baseline and Week 96</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score</title>
          <description>The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant’s perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Excludes participants who withdrew prior to 1 year (defined as stopping treatment prior to Week 48) of participation in the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="20.947"/>
                    <measurement group_id="O2" value="0.61" spread="19.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1529</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Wk 96 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL MSIS-29 physical score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96</title>
        <description>Whole brain volume as measured by MRI.</description>
        <time_frame>Week 24 and Week 96</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Includes those participants with an assessment at Weeks 24 and 96.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96</title>
          <description>Whole brain volume as measured by MRI.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment. Includes those participants with an assessment at Weeks 24 and 96.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.656"/>
                    <measurement group_id="O2" value="-0.66" spread="0.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only participants with BL brain volume are included in the p-value calculation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2424</p_value>
            <p_value_desc>natalizumab participants had a baseline after 6 months of treatment and the placebo-to-natalizumab group had a baseline of initiation of treatment</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo groups at Week 96 is based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or &gt;=6) and BL brain volume.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores</title>
        <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:
an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or
an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.
A confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores</title>
          <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:
an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or
an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.
A confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="25.2" upper_limit="33.7"/>
                    <measurement group_id="O2" value="25" lower_limit="20.6" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1052</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for baseline EDSS (&lt;=5.5 or &gt;=6).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants With Disability Worsening at 156 Weeks</title>
        <description>Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS &gt; 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.</description>
        <time_frame>Week 156</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants With Disability Worsening at 156 Weeks</title>
          <description>Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS &gt; 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed on ≥1 of EDSS, T25FW, 9HPT at 156 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="55.2" upper_limit="66.7"/>
                    <measurement group_id="O2" value="52" lower_limit="45.8" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on EDSS at 156 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="18.3" upper_limit="28.4"/>
                    <measurement group_id="O2" value="18" lower_limit="13.8" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on T25FW at 156 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="40.1" upper_limit="51.9"/>
                    <measurement group_id="O2" value="41" lower_limit="35.2" upper_limit="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on 9HPT (either hand) at 156 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="23.1" upper_limit="33.8"/>
                    <measurement group_id="O2" value="19" lower_limit="14.4" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on 9HPT (dominant hand) at 156 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="13.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="12" lower_limit="8.0" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed on 9HPT (non-dominant hand) at 156 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="13.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="13" lower_limit="9.2" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on ≥ 1 of EDSS, T25FW, or 9HPT at 156 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0205</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on EDSS at 156 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1305</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on T25FW at 156 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1988</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on 9HPT (either hand) at 156 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors onm 9HPT (dominant hand) at 156 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0540</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confirmed progressors on 9HPT (non-dominant hand) at 156 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1410</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression, adjusted for Baseline EDSS (&lt;=5.5 or &gt;=6) and/or T25FW and/or 9HPT (either hand).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>active/placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in T25FW</title>
        <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in T25FW</title>
          <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n=255, 264</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.80" spread="35.111"/>
                    <measurement group_id="O2" value="7.78" spread="21.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=39, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.01" spread="56.582"/>
                    <measurement group_id="O2" value="9.01" spread="22.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 156; n=156, 135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.67" spread="42.510"/>
                    <measurement group_id="O2" value="16.26" spread="26.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 204; n=25, 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.06" spread="66.275"/>
                    <measurement group_id="O2" value="20.89" spread="28.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 156; n=99, 129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="3.804"/>
                    <measurement group_id="O2" value="-1.09" spread="3.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 204; n=14, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="5.917"/>
                    <measurement group_id="O2" value="-1.67" spread="4.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0273</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL T25FW.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1974</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL T25FW.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2506</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL T25FW.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in T25FW</title>
        <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in T25FW</title>
          <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL at Week 156; n=255, 264</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.52" spread="166.191"/>
                    <measurement group_id="O2" value="55.91" spread="130.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL at Week 204; n=39, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.72" spread="272.117"/>
                    <measurement group_id="O2" value="71.09" spread="177.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL at Week 156; n=156, 135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.05" spread="195.138"/>
                    <measurement group_id="O2" value="113.51" spread="160.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL at Week 204; n=25, 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.78" spread="316.344"/>
                    <measurement group_id="O2" value="158.91" spread="228.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL at Week 156; n=99, 129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.68" spread="21.708"/>
                    <measurement group_id="O2" value="-4.37" spread="25.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL at Week 204; n=14, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.09" spread="26.591"/>
                    <measurement group_id="O2" value="-7.94" spread="29.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0960</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL T25FW.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4957</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL T25FW.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2916</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL T25FW.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)</title>
        <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)</title>
          <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n= 257, 271</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="27.728"/>
                    <measurement group_id="O2" value="2.12" spread="16.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=39, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="7.923"/>
                    <measurement group_id="O2" value="2.65" spread="16.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 156; n=158, 138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.12" spread="33.675"/>
                    <measurement group_id="O2" value="5.01" spread="20.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 204; n=24, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="9.187"/>
                    <measurement group_id="O2" value="6.03" spread="21.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 156; n=99, 133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="9.543"/>
                    <measurement group_id="O2" value="-0.89" spread="10.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 204; n=15, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="4.153"/>
                    <measurement group_id="O2" value="-0.73" spread="4.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall, Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1119</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1129</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2351</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (dominant hand).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)</title>
        <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)</title>
          <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n=257, 271</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.32" spread="59.727"/>
                    <measurement group_id="O2" value="5.25" spread="32.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=39, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="19.193"/>
                    <measurement group_id="O2" value="6.87" spread="32.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 156; n=158, 138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.87" spread="72.621"/>
                    <measurement group_id="O2" value="12.84" spread="40.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 204; n=24, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="20.247"/>
                    <measurement group_id="O2" value="16.25" spread="41.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 156; n=99, 133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="17.661"/>
                    <measurement group_id="O2" value="-2.63" spread="19.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 204; n=15, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="12.560"/>
                    <measurement group_id="O2" value="-2.52" spread="15.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0261</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0585</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6095</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (dominant hand).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)</title>
        <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)</title>
          <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n=254, 269</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="32.910"/>
                    <measurement group_id="O2" value="4.62" spread="30.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=40, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="16.952"/>
                    <measurement group_id="O2" value="4.91" spread="33.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 156; n=155, 137</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" spread="39.513"/>
                    <measurement group_id="O2" value="11.25" spread="38.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 204; n=25, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="17.474"/>
                    <measurement group_id="O2" value="17.20" spread="34.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 156; n=99, 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.17" spread="13.999"/>
                    <measurement group_id="O2" value="-2.26" spread="16.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 204; n=15, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.04" spread="13.491"/>
                    <measurement group_id="O2" value="-7.39" spread="28.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7230</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (non-dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8781</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (non-dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2751</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (non-dominant hand).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)</title>
        <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)</title>
          <description>The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n=254, 269</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.87" spread="64.959"/>
                    <measurement group_id="O2" value="11.04" spread="47.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=40, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="28.755"/>
                    <measurement group_id="O2" value="18.57" spread="62.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 156; n=155, 137</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.33" spread="79.957"/>
                    <measurement group_id="O2" value="23.51" spread="60.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 204; n=25, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.87" spread="31.050"/>
                    <measurement group_id="O2" value="43.12" spread="80.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 156; n=99, 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.63" spread="14.765"/>
                    <measurement group_id="O2" value="-1.89" spread="24.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 204; n=15, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.98" spread="18.188"/>
                    <measurement group_id="O2" value="-5.98" spread="16.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5051</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (non-dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7283</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (non-dominant hand).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1666</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 9HPT (non-dominant hand).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in EDSS</title>
        <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in EDSS</title>
          <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n=260, 275</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.746"/>
                    <measurement group_id="O2" value="0.06" spread="0.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=40, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.895"/>
                    <measurement group_id="O2" value="0.15" spread="0.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 156; n=162, 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.631"/>
                    <measurement group_id="O2" value="0.36" spread="0.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group: Change from BL to Week 204; n=25, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.542"/>
                    <measurement group_id="O2" value="0.68" spread="0.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 156; n=98, 134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.718"/>
                    <measurement group_id="O2" value="-0.25" spread="0.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group: Change from BL to Week 204; n=15, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="1.150"/>
                    <measurement group_id="O2" value="-0.38" spread="0.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4330</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7122</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3861</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in EDSS</title>
        <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in EDSS</title>
          <description>The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Change from BL to Week 156; n=260, 275</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="15.188"/>
                    <measurement group_id="O2" value="1.65" spread="16.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Change from BL to Week 204; n=40, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="17.889"/>
                    <measurement group_id="O2" value="2.91" spread="18.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group Change from BL to Week 156; n=162, 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="13.513"/>
                    <measurement group_id="O2" value="7.30" spread="15.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CP Group Change from BL to Week 204; n=25, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" spread="10.711"/>
                    <measurement group_id="O2" value="13.18" spread="13.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group Change from BL to Week 156; n=98, 134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.47" spread="13.951"/>
                    <measurement group_id="O2" value="-4.29" spread="15.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NP Group Change from BL to Week 204; n=15, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.53" spread="22.953"/>
                    <measurement group_id="O2" value="-7.35" spread="17.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7225</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9121</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NP Group: Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2594</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA, adjusted for BL EDSS (≤5.5 or ≥6).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)</title>
        <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.</description>
        <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)</title>
          <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 156; n=272, 289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="117.55"/>
                    <measurement group_id="O2" value="-40.4" spread="219.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 204; n=272, 290</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3" spread="119.40"/>
                    <measurement group_id="O2" value="-40.7" spread="219.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8066</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo groups at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL 6MWT.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in the 6MWT</title>
        <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Actual change from baseline tables are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data on Weeks 204 and 252, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in the 6MWT</title>
          <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.</description>
          <population>Actual change from baseline tables are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data on Weeks 204 and 252, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score</title>
        <description>The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient’s perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
        <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2) who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score</title>
          <description>The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient’s perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2) who had an assessment at Baseline and given time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="20.943"/>
                    <measurement group_id="O2" value="0.05" spread="20.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to from BL Week 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="21.018"/>
                    <measurement group_id="O2" value="-0.28" spread="20.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7084</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL MSIS-29 physical score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score</title>
        <description>The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient’s perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
        <time_frame>Baseline (Part 1) and Weeks 156, 204</time_frame>
        <population>Actual change from baseline tables are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data on Weeks 204 and 252, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score</title>
          <description>The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient’s perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.</description>
          <population>Actual change from baseline tables are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data on Weeks 204 and 252, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)</title>
        <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).</description>
        <time_frame>Baseline (Part 1) and every 4 weeks from Week 108 to Week 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2). Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)</title>
          <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2). Missing values were imputed using last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="14.19"/>
                    <measurement group_id="O2" value="15.5" spread="13.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="13.72"/>
                    <measurement group_id="O2" value="15.1" spread="13.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="13.84"/>
                    <measurement group_id="O2" value="15.3" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="14.23"/>
                    <measurement group_id="O2" value="15.3" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="14.02"/>
                    <measurement group_id="O2" value="15.7" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="14.49"/>
                    <measurement group_id="O2" value="15.7" spread="13.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="14.52"/>
                    <measurement group_id="O2" value="15.6" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="14.56"/>
                    <measurement group_id="O2" value="16.3" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="14.98"/>
                    <measurement group_id="O2" value="16.4" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="15.23"/>
                    <measurement group_id="O2" value="16.2" spread="14.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 148</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="15.34"/>
                    <measurement group_id="O2" value="16.3" spread="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="14.98"/>
                    <measurement group_id="O2" value="16.3" spread="14.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="13.10"/>
                    <measurement group_id="O2" value="12.3" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="14.92"/>
                    <measurement group_id="O2" value="16.2" spread="14.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 164</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="15.21"/>
                    <measurement group_id="O2" value="16.3" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="15.52"/>
                    <measurement group_id="O2" value="16.4" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 172</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="15.40"/>
                    <measurement group_id="O2" value="16.3" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="15.58"/>
                    <measurement group_id="O2" value="16.3" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="15.23"/>
                    <measurement group_id="O2" value="16.4" spread="14.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 184</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="15.34"/>
                    <measurement group_id="O2" value="16.3" spread="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="15.38"/>
                    <measurement group_id="O2" value="16.4" spread="14.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="15.46"/>
                    <measurement group_id="O2" value="16.3" spread="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 196</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="15.45"/>
                    <measurement group_id="O2" value="16.3" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="15.47"/>
                    <measurement group_id="O2" value="16.3" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="15.43"/>
                    <measurement group_id="O2" value="16.3" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3465</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active and placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (&lt;=5.5 or&gt;=6) and BL SDMT.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in the SDMT</title>
        <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).</description>
        <time_frame>Baseline (Part 1) and every 4 weeks from Week 108 to Week 204</time_frame>
        <population>Actual change from baseline tables are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data up to Weeks 204 and 252, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary, and the analysis was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in the SDMT</title>
          <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).</description>
          <population>Actual change from baseline tables are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data up to Weeks 204 and 252, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary, and the analysis was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment – Multiple Sclerosis (WPAI-MS) Questionnaire</title>
        <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
        <time_frame>Part 2 Baseline (Week 108) and Weeks 156 and 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2) who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment – Multiple Sclerosis (WPAI-MS) Questionnaire</title>
          <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2) who had an assessment at Baseline and given time point.</population>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism: Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="12.80"/>
                    <measurement group_id="O2" value="1.4" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absenteeism: Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="14.61"/>
                    <measurement group_id="O2" value="4.1" spread="17.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absenteeism: Week 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="14.61"/>
                    <measurement group_id="O2" value="4.2" spread="16.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism: Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="12.10"/>
                    <measurement group_id="O2" value="30.9" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism: Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="12.17"/>
                    <measurement group_id="O2" value="33.0" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism: Week 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="12.29"/>
                    <measurement group_id="O2" value="32.2" spread="13.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productivity Loss: Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="12.36"/>
                    <measurement group_id="O2" value="31.2" spread="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productivity Loss: Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="13.54"/>
                    <measurement group_id="O2" value="33.9" spread="15.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productivity Loss: Week 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="13.66"/>
                    <measurement group_id="O2" value="33.3" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment: Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="24.78"/>
                    <measurement group_id="O2" value="58.0" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment: Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="26.49"/>
                    <measurement group_id="O2" value="58.5" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment: Week 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" spread="25.15"/>
                    <measurement group_id="O2" value="59.8" spread="23.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire</title>
        <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
        <time_frame>Part 2 Baseline (Week 108) and Weeks 156 and 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire</title>
          <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism: Change at Week 156; n=18,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="116.81"/>
                    <measurement group_id="O2" value="-7.4" spread="95.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absenteeism: Change at Week 204; n=18, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="116.90"/>
                    <measurement group_id="O2" value="151.5" spread="457.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism: Change at Week 156; n=264, 285</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="50.08"/>
                    <measurement group_id="O2" value="14.4" spread="90.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism: Change at Week 204; n=264, 285</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="51.23"/>
                    <measurement group_id="O2" value="7.4" spread="58.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WPL: Change at Week 156; n=264,286</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="51.73"/>
                    <measurement group_id="O2" value="16.8" spread="95.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WPL: Change at Week 204; n=264, 286</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="53.44"/>
                    <measurement group_id="O2" value="10.6" spread="69.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AI: Change at Week 156; n=264, 284</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="95.68"/>
                    <measurement group_id="O2" value="15.7" spread="83.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AI: Change at Week 204; n=264, 284</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="88.56"/>
                    <measurement group_id="O2" value="20.4" spread="99.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume</title>
        <description>Whole brain volume as measured by MRI.</description>
        <time_frame>Week 24 (Part 1) and Weeks 156 and 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume</title>
          <description>Whole brain volume as measured by MRI.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Week 24 to Week 156; n=155, 175</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.164" spread="0.8228"/>
                    <measurement group_id="O2" value="-0.948" spread="0.7193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 24 to Week 204; n=28, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.687" spread="1.2872"/>
                    <measurement group_id="O2" value="-1.517" spread="0.8412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage change from Week 24 to Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <p_value_desc>natalizumab participants had a baseline after 6 months of treatment and the placebo-to-natalizumab group had a baseline of initiation of treatment</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL normalized brain volume.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume</title>
        <description>Whole grey matter brain volume as measured by MRI.</description>
        <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume</title>
          <description>Whole grey matter brain volume as measured by MRI.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 156; n=149, 170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.566" spread="0.9303"/>
                    <measurement group_id="O2" value="-1.514" spread="0.8969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 204; n=26, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.883" spread="1.4222"/>
                    <measurement group_id="O2" value="-2.086" spread="0.9068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage hange from Baseline to Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5034</p_value>
            <p_value_desc>natalizumab participants had a baseline after 6 months of treatment and the placebo-to-natalizumab group had a baseline of initiation of treatment</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>p-value for comparison between active &amp; placebo at Week 156 based on ANCOVA model, adjusted for BL EDSS (≤5.5 or ≥6) &amp; BL WGM brain volume</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Summary of New/Enlarging T2 Lesion Counts</title>
        <description>New or enlarging T2 lesions as measured by MRI.</description>
        <time_frame>Baseline (Part 1) up to Week 204</time_frame>
        <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Summary of New/Enlarging T2 Lesion Counts</title>
          <description>New or enlarging T2 lesions as measured by MRI.</description>
          <population>Intent to treat population: all participants who were randomized and received at least 1 infusion of study treatment (Part 2); n=participants who had an assessment at Baseline and given time point.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 24 compared to BL; n=272, 287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="4.24"/>
                    <measurement group_id="O2" value="0.6" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48 compared to Week 24; n=272, 289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.47"/>
                    <measurement group_id="O2" value="0.0" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 72 compared to Week 48; n=271, 287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.76"/>
                    <measurement group_id="O2" value="0.0" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 96 compared to Week 72; n=269, 284</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.33"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 108 compared to Week 96; n=269, 288</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.38"/>
                    <measurement group_id="O2" value="0.0" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 156 compared to Week 108; n=245, 258</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.79"/>
                    <measurement group_id="O2" value="0.0" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 204 compared to Week 156; n=50, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.20"/>
                    <measurement group_id="O2" value="0.0" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative count from BL to Week 204; n=274, 291</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="16.04"/>
                    <measurement group_id="O2" value="0.7" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 156</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>p-value for comparison between the active and placebo groups at Week 156 compared to Week 108 is based on negative binomial regression model, adjusted for baseline EDSS (&lt;=5.5 or &gt;=6) and baseline volume of T2 lesions.</p_value_desc>
            <method>negative binomial regression model</method>
            <method_desc>natalizumab participants had a baseline after 6 months of treatment and the placebo-to-natalizumab group had a baseline of initiation of treatment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions</title>
        <description>New or enlarging T2 lesions as measured by MRI.</description>
        <time_frame>Baseline (Part 1) and Weeks 156 and 204</time_frame>
        <population>Summary new/enlarging T2 lesion values are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data up to Week 204, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary, and the analysis was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Natalizumab 300 mg</title>
            <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions</title>
          <description>New or enlarging T2 lesions as measured by MRI.</description>
          <population>Summary new/enlarging T2 lesion values are provided in previous Outcome Measure. Due to the nature of self-selected population in an extension trial and sparse data up to Week 204, further tabulations on percentage changes on these endpoints were deemed less meaningful and unnecessary, and the analysis was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are captured through the last study visit; participants were followed through Week 228, or 24 weeks following last dose of study treatment, or premature withdrawal.</time_frame>
      <desc>Treatment-emergent adverse events only are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Part 1: participants were randomized to receive placebo IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Natalizumab 300 mg</title>
          <description>Part 1: participants were randomized to receive 300 mg of natalizumab IV every 4 weeks for 96 weeks. Part 2: participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Small intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Ear injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Insulin-requiring type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Signet-ring cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Secondary progressive multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Tonic convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Uhthoff's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Joint surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Limb operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="347" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="325" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

